Cargando…

Sleep Duration, Lipid Profile and Insulin Resistance: Potential Role of Lipoprotein(a)

Lipoprotein (a) (Lp(a)) is considered a genetic factor for cardiovascular disease playing an important role in atherogenesis and thrombosis, but the evidence about its association with sleep duration is controversial. We evaluated the relation between self-reported sleep duration and Lp(a). Among 16...

Descripción completa

Detalles Bibliográficos
Autores principales: Korostovtseva, Lyudmila, Alieva, Asiiat, Rotar, Oxana, Bochkarev, Mikhail, Boyarinova, Maria, Sviryaev, Yurii, Konradi, Aleksandra, Shlyakhto, Eugene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369827/
https://www.ncbi.nlm.nih.gov/pubmed/32630105
http://dx.doi.org/10.3390/ijms21134680
_version_ 1783560858338590720
author Korostovtseva, Lyudmila
Alieva, Asiiat
Rotar, Oxana
Bochkarev, Mikhail
Boyarinova, Maria
Sviryaev, Yurii
Konradi, Aleksandra
Shlyakhto, Eugene
author_facet Korostovtseva, Lyudmila
Alieva, Asiiat
Rotar, Oxana
Bochkarev, Mikhail
Boyarinova, Maria
Sviryaev, Yurii
Konradi, Aleksandra
Shlyakhto, Eugene
author_sort Korostovtseva, Lyudmila
collection PubMed
description Lipoprotein (a) (Lp(a)) is considered a genetic factor for cardiovascular disease playing an important role in atherogenesis and thrombosis, but the evidence about its association with sleep duration is controversial. We evaluated the relation between self-reported sleep duration and Lp(a). Among 1600 participants of the population-based sample, we selected 1427 subjects without previously known cardiovascular events, who answered the questions about their sleep duration; had valid lipid profile results (total cholesterol, low- and high-density lipoproteins, Lp(a), apolipoprotein AI (ApoAI), ApoB, and ApoB/ApoAI); and did not take lipid-lowering drugs (mean age 46 ± 12 years). We performed a structured interview, which included questions about lifestyle, medical history, complaints, and sleep duration (How long have you been sleeping per night during the last month?). Sleep duration was classified as follows: <6 h/night—short, 6–9 h/night—normal, and ≥10 h/night—long. Overall, 73 respondents (5.2%) were short-sleepers and 69 (4.8%) long-sleepers. Males were slightly more prevalent among short-sleepers. The groups matched by age, body mass index, blood pressure, diabetes mellitus, and hypertension rate. Short-sleepers had lower rates of high total cholesterol (≥5.0 mmol/L), lower Lp(a) levels and lower rates of increased Lp(a) ≥0.5 g/L, and higher insulin and insulin resistance (assessed by the homeostatic model assessment for insulin resistance (HOMA-IR)). ApoAI, ApoB, their ratio, and other lab tests were similar in the groups. The multinomial logistic regression demonstrated that only the short sleep duration was independently (odds ratio (OR) 0.29, 95% confidence interval (CI) (0.09–0.91), p = 0.033) associated with Lp(a) (χ(2) = 41.58, p = 0.003). Other influencing factors were smoking and HOMA-IR. Such an association was not found for long-sleepers. In conclusion, a short-sleep duration is associated with Lp(a). The latter might mediate the higher insulin resistance and higher cardiometabolic risks in short-sleepers.
format Online
Article
Text
id pubmed-7369827
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73698272020-07-21 Sleep Duration, Lipid Profile and Insulin Resistance: Potential Role of Lipoprotein(a) Korostovtseva, Lyudmila Alieva, Asiiat Rotar, Oxana Bochkarev, Mikhail Boyarinova, Maria Sviryaev, Yurii Konradi, Aleksandra Shlyakhto, Eugene Int J Mol Sci Article Lipoprotein (a) (Lp(a)) is considered a genetic factor for cardiovascular disease playing an important role in atherogenesis and thrombosis, but the evidence about its association with sleep duration is controversial. We evaluated the relation between self-reported sleep duration and Lp(a). Among 1600 participants of the population-based sample, we selected 1427 subjects without previously known cardiovascular events, who answered the questions about their sleep duration; had valid lipid profile results (total cholesterol, low- and high-density lipoproteins, Lp(a), apolipoprotein AI (ApoAI), ApoB, and ApoB/ApoAI); and did not take lipid-lowering drugs (mean age 46 ± 12 years). We performed a structured interview, which included questions about lifestyle, medical history, complaints, and sleep duration (How long have you been sleeping per night during the last month?). Sleep duration was classified as follows: <6 h/night—short, 6–9 h/night—normal, and ≥10 h/night—long. Overall, 73 respondents (5.2%) were short-sleepers and 69 (4.8%) long-sleepers. Males were slightly more prevalent among short-sleepers. The groups matched by age, body mass index, blood pressure, diabetes mellitus, and hypertension rate. Short-sleepers had lower rates of high total cholesterol (≥5.0 mmol/L), lower Lp(a) levels and lower rates of increased Lp(a) ≥0.5 g/L, and higher insulin and insulin resistance (assessed by the homeostatic model assessment for insulin resistance (HOMA-IR)). ApoAI, ApoB, their ratio, and other lab tests were similar in the groups. The multinomial logistic regression demonstrated that only the short sleep duration was independently (odds ratio (OR) 0.29, 95% confidence interval (CI) (0.09–0.91), p = 0.033) associated with Lp(a) (χ(2) = 41.58, p = 0.003). Other influencing factors were smoking and HOMA-IR. Such an association was not found for long-sleepers. In conclusion, a short-sleep duration is associated with Lp(a). The latter might mediate the higher insulin resistance and higher cardiometabolic risks in short-sleepers. MDPI 2020-06-30 /pmc/articles/PMC7369827/ /pubmed/32630105 http://dx.doi.org/10.3390/ijms21134680 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Korostovtseva, Lyudmila
Alieva, Asiiat
Rotar, Oxana
Bochkarev, Mikhail
Boyarinova, Maria
Sviryaev, Yurii
Konradi, Aleksandra
Shlyakhto, Eugene
Sleep Duration, Lipid Profile and Insulin Resistance: Potential Role of Lipoprotein(a)
title Sleep Duration, Lipid Profile and Insulin Resistance: Potential Role of Lipoprotein(a)
title_full Sleep Duration, Lipid Profile and Insulin Resistance: Potential Role of Lipoprotein(a)
title_fullStr Sleep Duration, Lipid Profile and Insulin Resistance: Potential Role of Lipoprotein(a)
title_full_unstemmed Sleep Duration, Lipid Profile and Insulin Resistance: Potential Role of Lipoprotein(a)
title_short Sleep Duration, Lipid Profile and Insulin Resistance: Potential Role of Lipoprotein(a)
title_sort sleep duration, lipid profile and insulin resistance: potential role of lipoprotein(a)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369827/
https://www.ncbi.nlm.nih.gov/pubmed/32630105
http://dx.doi.org/10.3390/ijms21134680
work_keys_str_mv AT korostovtsevalyudmila sleepdurationlipidprofileandinsulinresistancepotentialroleoflipoproteina
AT alievaasiiat sleepdurationlipidprofileandinsulinresistancepotentialroleoflipoproteina
AT rotaroxana sleepdurationlipidprofileandinsulinresistancepotentialroleoflipoproteina
AT bochkarevmikhail sleepdurationlipidprofileandinsulinresistancepotentialroleoflipoproteina
AT boyarinovamaria sleepdurationlipidprofileandinsulinresistancepotentialroleoflipoproteina
AT sviryaevyurii sleepdurationlipidprofileandinsulinresistancepotentialroleoflipoproteina
AT konradialeksandra sleepdurationlipidprofileandinsulinresistancepotentialroleoflipoproteina
AT shlyakhtoeugene sleepdurationlipidprofileandinsulinresistancepotentialroleoflipoproteina